Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 20,000 Shares

Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 20,000 shares of Atara Biotherapeutics stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $46.80, for a total value of $936,000.00. Following the sale, the chief executive officer now directly owns 808,675 shares of the company’s stock, valued at $37,845,990. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Atara Biotherapeutics Inc (ATRA) traded up $3.30 during trading on Wednesday, hitting $48.35. The stock had a trading volume of 1,427,869 shares, compared to its average volume of 1,256,386. Atara Biotherapeutics Inc has a fifty-two week low of $11.80 and a fifty-two week high of $49.90. The stock has a market cap of $1,480.00, a P/E ratio of -13.93 and a beta of 2.71.

A number of analysts have issued reports on the company. Citigroup raised Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price target for the company in a report on Wednesday, January 3rd. Canaccord Genuity reissued a “positive” rating and issued a $70.00 target price (up from $47.00) on shares of Atara Biotherapeutics in a report on Friday, January 19th. BidaskClub raised Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Cowen started coverage on Atara Biotherapeutics in a report on Friday, January 26th. They issued an “outperform” rating for the company. Finally, Zacks Investment Research downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $30.60.

Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in shares of Atara Biotherapeutics in the 3rd quarter valued at about $142,000. Russell Investments Group Ltd. purchased a new stake in shares of Atara Biotherapeutics in the 3rd quarter valued at about $170,000. Voya Investment Management LLC lifted its holdings in shares of Atara Biotherapeutics by 16.2% in the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 1,651 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Atara Biotherapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after acquiring an additional 1,369 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Atara Biotherapeutics by 2.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock valued at $304,000 after acquiring an additional 610 shares during the period. 69.58% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 20,000 Shares” was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/02/14/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-20000-shares.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply